Health ❯Healthcare ❯Pharmaceuticals

Clinical Trials

Weight Loss Drugs Drug Development Major Depressive Disorder Gene Therapy Alzheimer's Disease Drug Safety Tirzepatide Duchenne Muscular Dystrophy Efficacy Studies Cardiovascular Health

Orexin-2 Agonists Lift Wakefulness in Narcolepsy as Takeda Leads With Late-Stage Wins

Takeda targets a March filing after trials showed longer wakefulness with large reductions in cataplexy.

Pumitamig Shows High Response in First-Line Small Cell Lung Cancer Phase 2

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

ArcaScience Raises $7 Million Seed to Expand AI Drug Benefit–Risk Platform

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials

Viking’s Oral Obesity Pill Shows Strong Weight Loss but High Dropouts, Triggering Stock Rout

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Four-Year Lecanemab Study Shows Growing Cognitive Benefits and Stable Safety

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

FDA Advisers Recommend Against Approval of GSK’s Myeloma Drug Blenrep

AstraZeneca’s Baxdrostat Delivers Significant Blood Pressure Reductions in Phase 3 Trial for Resistant Hypertension

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

BMJ Reveals Data Flaws in Pivotal Ticagrelor FDA Approval Studies

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death

Duke's SBI-810 Shows Promise as Non-Opioid Painkiller in Preclinical Studies

Single-Dose Flu Drug Proven to Reduce Household Transmission by 30%